Hereditary Hemorrhagic Telangiectasia: Causes, Symptoms, and Treatment

Understanding Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia, commonly known as HHT or Osler-Weber-Rendu syndrome, is a genetic disorder that affects the development of blood vessels throughout the body. This inherited condition causes some blood vessels to develop abnormally, resulting in direct connections between arteries and veins without the normal bridging capillaries that typically regulate blood flow. People with HHT may experience a range of complications, from mild nosebleeds to life-threatening internal bleeding. Understanding this condition is essential for proper management and prevention of serious complications.

HHT is an autosomal dominant genetic disorder, meaning that a person needs only one copy of the mutated gene from either parent to develop the condition. The prevalence of HHT ranges from approximately one in 5,000 to one in 8,000 people, making it a relatively rare condition. However, due to its hereditary nature and potential for serious complications, early diagnosis and ongoing management are crucial for individuals with this disorder.

Causes and Genetic Basis of HHT

HHT results from mutations in genes that provide instructions for producing proteins found in the lining of blood vessels. When these genes are faulty, they either fail to produce the necessary proteins or produce abnormal versions that cannot function properly. This disruption in protein production leads to the characteristic abnormal blood vessel development seen in HHT.

Scientists identified the genetic basis of HHT in the mid-1990s, discovering that mutations on either chromosome 9 or chromosome 12 are responsible for most cases of the condition. Chromosome 9 mutations affect the endoglin gene (HHT-1), while chromosome 12 mutations involve the activin-like kinase gene (HHT-2). Additionally, at least three other abnormal genes have been identified as causes of HHT, contributing to the genetic diversity of this condition.

Types of HHT

There are three main classifications of HHT based on the genetic mutations involved:

• Type 1 (HHT-1) — Caused by mutations in the endoglin gene on chromosome 9. This type typically presents earlier and often involves pulmonary arteriovenous malformations.
• Type 2 (HHT-2) — Caused by mutations in the ACVRL1 (ALK1) gene on chromosome 12. This type may present later in life and tends to have different organ involvement patterns.
• HHT-Juvenile Polyposis Syndrome — Caused by mutations in the SMAD4 gene. This rare variant combines features of HHT with juvenile polyposis and typically involves more severe complications.

Symptoms and Clinical Manifestations

The symptoms of HHT vary significantly from person to person, depending on which blood vessels are affected and the severity of the abnormalities. Some individuals may experience minimal symptoms, while others develop serious, life-threatening complications. Because many people have few or no obvious symptoms initially, HHT often goes undiagnosed until serious complications occur.

Nosebleeds

The most common symptom of HHT is frequent nosebleeds, affecting approximately 90 percent of people with the condition. Nosebleeds occur because of abnormal blood vessels within the lining of the nose, called nasal telangiectasias. These nosebleeds often begin in childhood or teenage years and can occur multiple times daily. The frequency and severity of nosebleeds typically increase with age. While most are mild to moderate, some can be severe and prolonged, leading to significant blood loss and complications such as iron deficiency anemia.

Visible Skin Manifestations

Many individuals with HHT develop visible abnormal blood vessels on their skin, particularly on the hands, fingertips, face, lips, tongue, and inside the mouth. These appear as delicate red or purplish spots and are called telangiectasias. These tiny, abnormal blood vessels characteristically lighten briefly when touched or pressed. While these skin manifestations are primarily cosmetic concerns, they serve as important diagnostic clues for healthcare providers.

Internal Bleeding and Anemia

Approximately 80 percent of people with HHT develop telangiectasias in the stomach and intestines (gastrointestinal tract), though only about 20 percent experience bleeding from these sites, usually later in life. When bleeding occurs in the gastrointestinal tract, individuals may notice dark stools or blood in the stool. Both nosebleeds and gastrointestinal bleeding can cause iron deficiency anemia, resulting in fatigue, shortness of breath, chest pain, and lightheadedness.

Complications from Organ-Specific Involvement

When abnormal blood vessels develop in larger organ systems, they can cause serious complications. Arteriovenous malformations (AVMs) in the lungs may lead to shortness of breath, low oxygen levels, and coughing up blood. Brain AVMs can cause ischemic strokes, brain abscesses, transient ischemic attacks (TIAs), seizures, and headaches or migraines. Liver involvement, while common (most people with HHT have liver vascular malformations), causes symptoms in less than 5 percent of patients but may include heart failure, abdominal pain, fluid in the abdomen (ascites), and enlarged blood vessels in the esophagus (varices).

Diagnosis of HHT

Diagnosing HHT typically begins when healthcare providers observe characteristic symptoms or signs. The most common initial presentation is spontaneous and recurrent nosebleeds. Doctors also look for telangiectasias on the hands, fingers, lips, and inside the mouth.

Diagnostic Criteria

A clinical diagnosis of HHT is established when a patient demonstrates three of the following four major criteria:

• Frequent nosebleeds (spontaneous and recurrent)
• Telangiectasias found on the mouth, lips, tongue, fingertips, or other mucocutaneous surfaces
• Internal AVMs found in the lungs, brain, liver, or gastrointestinal tract
• A family history of HHT in a first-degree relative

Additionally, genetic testing can confirm HHT by identifying mutations in the relevant genes. Screening for internal AVMs often involves imaging studies such as chest X-rays, CT scans, or MRI to detect pulmonary, cerebral, or hepatic involvement. Some patients may undergo echocardiography or other specialized imaging to assess the extent of vascular abnormalities.

Treatment and Management Options

While there is currently no cure for HHT, various treatment options can help manage symptoms and prevent serious complications. The approach to treatment depends on the severity of symptoms and which organs are affected.

Managing Nosebleeds

The majority of nosebleeds associated with HHT can be effectively managed with conservative measures. These include nasal lubricants, humidification, and maintaining adequate moisture in the nasal passages. Laser therapy can cauterize bleeding vessels in the nose, reducing the frequency and severity of epistaxis. Medications such as topical treatments or systemic agents may also be prescribed. For more severe and treatment-resistant nosebleeds, advanced medications that prevent blood vessel formation may be necessary.

Managing Internal Bleeding

Gastrointestinal bleeding requires careful management to prevent anemia and its complications. Iron supplementation is essential when bleeding occurs, and some patients may require blood transfusions if bleeding is severe. Medications that reduce stomach acid or promote clotting may be prescribed. Regular monitoring of hemoglobin levels is important for detecting anemia early.

Cardiovascular Management

For patients with pulmonary AVMs, treatment may include anticoagulation therapy to prevent blood clots, as AVMs increase the risk of paradoxical embolism. Some pulmonary AVMs can be treated with catheter-based embolization procedures to close the abnormal vessels. Patients with cerebral AVMs require careful monitoring and may need neurosurgical intervention if the AVMs pose a significant risk of rupture.

Liver Disease Management

Most people with liver involvement remain asymptomatic and require only monitoring. However, those who develop symptoms may need specific interventions depending on the type of liver involvement. Regular assessment of liver function through blood tests and imaging is recommended for patients with known hepatic involvement.

Living with HHT: Practical Considerations

People with HHT should take several precautions to minimize complications. Avoiding nasal trauma, using humidifiers to keep nasal passages moist, and maintaining good hydration can help reduce nosebleed frequency. Iron-rich diet and iron supplementation are important for preventing anemia. Regular follow-up appointments with healthcare providers familiar with HHT are essential for monitoring the condition and adjusting treatment as needed.

Genetic counseling is recommended for individuals with HHT and their family members, as the condition has significant hereditary implications. Close relatives of affected individuals should be screened, as early detection of HHT allows for preventive measures and timely intervention.

Frequently Asked Questions

Q: Is HHT curable?

A: Currently, there is no cure for HHT. However, various treatments can effectively manage symptoms and prevent or minimize complications. Ongoing research continues to explore new therapeutic options.

Q: Will all children of an HHT parent develop the condition?

A: Since HHT is autosomal dominant, each child of an affected parent has a 50 percent chance of inheriting the condition. Genetic counseling can help families understand inheritance patterns and plan for screening.

Q: Can HHT be detected before symptoms appear?

A: Yes, genetic testing can identify HHT mutations in asymptomatic individuals. Family screening is recommended when HHT is diagnosed in one family member. Imaging studies can also detect internal AVMs before they cause symptoms.

Q: How often should people with HHT be monitored?

A: The frequency of monitoring depends on individual circumstances and the organs involved. Regular follow-up with specialists familiar with HHT is essential. Some patients may need annual evaluations, while others require more frequent assessment.

Q: What should I do if I suspect I have HHT?

A: If you experience frequent nosebleeds or have a family history of HHT, consult with your primary care physician. They can refer you to a specialist for proper evaluation and testing. Early diagnosis allows for appropriate management and prevention of complications.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete